

TABLE 192: PRURITUS

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Afdhal et al., 2014 ION-1	1	(6) SOF12 + LDV12	11	214	5%
		(7) SOF24 + LDV24	8	217	4%
		(10) SOF12 + LDV12 + RBV12	22	217	10%
		(11) SOF24 + LDV24 + RBV24	20	217	9%
Buti et al., 2014 OPTIMIZE	1	(32) T12 PR24-48 RGT q8	170	371	46%
		(33) T12 PR24-48 RGT q12	172	369	47%
Feld et al., 2014 SAPPHIRE-I	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	80	473	17%
Ferenci et al., 2014 PEARL-III	1b	(14) PAR/RIT12 + OMB12 + DAS12	25	209	12%
Ferenci et al., 2014 PEARL-IV	1a	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	10	100	10%
Fried et al., 2013 PILLAR	1	(1) PR48	35	77	45%
		(42) SIM12 PR24-48 RGT	30	77	39%
Gane et al., 2013-1 ELECTRON	2+3	(3) SOF12 + RBV12	1	10	10%
		(40) SOF12 + PR12	2	11	18%
Gane et al., 2013-3 ELECTRON	1	(3) SOF12 + RBV12	0	25	0%
Gane et al., 2014-1 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	2	25	8%
Jacobson et al., 2014 QUEST-1	1	(1) PR48	26	130	20%
		(42) SIM12 PR24-48 RGT	79	264	30%
Jacobson et al., 2011 ADVANCE	1	(1) PR48	131	361	36%
		(32) T12 PR24-48 RGT q8	181	363	50%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Kowdley et al., 2013 ATOMIC	1	(40) SOF12 + PR12	5	52	10%
Kowdley et al., 2014 ION-3	1	(6) SOF12 + LDV12	5	216	2%
		(8) SOF8 + LDV8	2	215	1%
		(9) SOF8 + LDV8 + RBV8	16	216	7%
Kumada et al., 2014	1b	(17) DCV24 + ASU24	NR	135	NR
Lawitz et al., 2013 NEUTRINO	1+4+5+6	(40) SOF12 + PR12	54	327	17%
Lawitz et al., 2013 FISSION	2+3	(3) SOF12 + RBV12	19	256	7%
		(70) PR24	42	243	17%
Lawitz et al., 2014 LONESTAR	1	(6) SOF12 + LDV12	0	19	0%
Lawitz et al., 2014 LONESTAR	1	(8) SOF8 + LDV8	0	20	0%
Lawitz et al., 2014 LONESTAR	1	(9) SOF8 + LDV8 + RBV8	0	21	0%
Lawitz et al., 2013-1 PROTON	1	(1) PR48	3	26	12%
		(41) SOF12 PR24-48 RGT	5	47	11%
Lawitz et al., 2013-2 PROTON	2+3	(40) SOF12 + PR12	3	25	12%
Lawitz et al., 2015-1 C-WORTHY	1	(57) GRZ12 + ELB12 (50 mg q.d.)	1	29	3%
Lawitz et al., 2015-1 C-WORTHY	1	(59) GRZ18 + ELB18 (50 mg q.d.)	2	31	6%
		(63) GRZ12 + ELB12 (50 mg q.d.) + RBV12	2	31	6%
		(65) GRZ18 + ELB18(50 mg q.d.) + RBV18	5	32	16%
Manns et al., 2014 HALLMARK-DUAL	1b	(17) DCV24 + ASU24	8	205	4%
Manns et al., 2014 QUEST-2	1	(1) PR48	36	134	27%
		(42) SIM12 PR24-48 RGT	66	257	26%
Marcellin et al., 2011	1	(32) T12 PR24-48 RGT q8	42	82	51%
Marcellin et al., 2011	1	(33) T12 PR24-48 RGT q12	45	79	57%
Osinusi et al., 2013 SPARE-1	1	(4) SOF24 + RBV24	1	10	10%
Osinusi et al., 2013 SPARE-2	1	(4) SOF24 + RBV24	3	25	12%
		(71) SOF24 + RBV (low dose) 24	0	25	0%
Poordad et al., 2011 SPRINT2	1	(1) PR48	98	363	27%
		(46) B24 PR28-48 RGT	87	368	24%
Sulkowski et al., 2015-1 C-WORTHY	1	(23) GRZ12 + ELB12 + RBV12	6	86	7%
		(57) GRZ12 + ELB12 (50 mg q.d.)	0	43	0%
		(61) GRZ8 + ELB8 (50 mg q.d.) + RBV8	6	30	20%
Sulkowski et al., 2015-2 C-WORTHY	1	(57) GRZ12 + ELB12 (50 mg q.d.)	0	30	0%
		(63) GRZ12 + ELB12 (50 mg q.d.) + RBV12	3	29	10%
Sulkowski et al., 2014-1 ^a	2+3	(3) SOF12 + RBV12	6	68	9%
Sulkowski et al., 2014-2	1	(4) SOF24 + RBV24	6	114	5%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Sulkowski et al., 2014	1	(19) DCV12 + SOF12	1	41	2%
Sulkowski et al., 2013-1+2 ^b	1	(1) PR48	2	22	9%
		(39) T12 PR48 q8	15	38	39%
Sulkowski et al., 2013	1	(1) PR48	3	34	9%
		(50) B44 PR48	12	64	19%
Zeuzem-1+2+3 et al., 2015 C-EDGE	1+4+6	(22) GRZ12 + ELB12	7	316	2%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; q.d. = once daily; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.

^a Data for ineligible treatment for genotype 3, (3) SOF12 + RBV12, are included.

^b Data for ineligible participants who receive efavirenz-based antiretroviral and 1,125 mg of telaprevir every 8 hours are also included.